TABLE 1

AbaR-type genomic island and antimicrobial resistance in non-baumannii Acinetobacter isolates harboring genomic islands

SpeciesIsolateTypeMIC (mg/liter) ofa:
IMPMEMTETCIPRIFAMKCPMCTRCAZP/TA/SPBCOLTIG
A. nosocomialisH06-681Tn6022ΔtniD216>64>644>128>64>128>64>256/464/32124
H09-1045AbaR4>64>64646423264<168>256/464/32224
E09-34AbaR4>64>64>64843264<168>256/4>64/32224
A. seiffertiiC044Tn616611>64>644>12816>128>64256/464/32122
C066Tn6022ΔtniD16328>64216>64>128>64>256/464/32284
  • a IMP, imipenem; MEM, meropenem; TET, tetracycline; CIP, ciprofloxacin; RIF, rifampin; AMK, amikacin; CPM, cefepime; CTR, ceftriaxone; CAZ, ceftazidime; P/T, piperacillin-tazobactam; A/S, ampicillin-sulbactam; PB, polymyxin B; COL, colistin; TIG, tigecycline. MICs in bold indicate resistance. The breakpoints of resistance are from CLSI guidelines (11) for most antimicrobial resistance (resistance defined as ≥16 mg/liter for both imipenem and meropenem). The criteria recommended by the CLSI for staphylococci were applied for rifampin (resistance defined as ≥4 mg/liter), and the criteria of the U.S. Food and Drug Administration (FDA) for Enterobacteriaceae were used for tigecycline (resistance defined as ≥8 mg/liter) (18).